TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05747534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide Acetate
Description: AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
Study: NCT05133700

Intervention type: OTHER
Intervention: Interview or focus group discussion
Description: There is no intervention. This is a qualitative piece of work only

Intervention type: OTHER
Intervention: Review of submitted medicines audit tools
Description: There is no intervention. This is a qualitative piece of work only
Study: NCT06525129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebellar stimulation group (CbSG)
Description: Anodal transcranial direct current stimulation was given using a portable battery-driven brain stimulator (The Brain Stimulator v3.0 Deluxe tDCS Kit, using Professional 3x3 inches Amrex Sponge Electrodes). Skin was prepared before application of electrodes by cleaning the skin surface using alcohol swabs. In cerebellar stimulation group (CbSG) a stimulation intensity of 2mA for duration of 20 minutes. In order to avoid sudden initiation and termination of the stimulation the first and last 10 seconds of anodal tDCS application, current will gradually fade in/fade out to avoid any sudden starting or stopping of the stimulation. For the CbSG active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right buccinator muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral (M1) Stimulation group (MSG)
Description: In the M1 Stimulation Group (MSG) a similar intensity of current with 2mA was applied for a period of 20 minutes. Skin was cleaned with alcohol swab ahead of placing the electrodes. The anode was positioned over the lesioned M1 motor cortex area (C3, International 10-20 system) while the cathode was placed over the contra-lateral supraorbital area. Due to the large size of electrodes, the active electrode covered the area of M1 for the hand, arm, trunk, and the LL. Ten sessions of anodal tDCS were applied over a duration of 2 weeks. The stimulation was applied during active participation of patients in Biodex balance training.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham Stimulation group (SSG)
Description: In Sham Stimulation group (SSG) Ten sessions of anodal tDCS were applied over a duration of 2 weeks having same intensity i.e., 2 mA stimulation was used for a period of 30 seconds and then gradually ramped-down and turned off for the rest of the treatment time of 20 minutes. The same procedure for skin preparation was used as in the other two groups. Electrode placement for SSG was same as in MSG for half of the patients i.e. 8 participants; anode will be placed over the left (dominant) lesioned M1 whereas the cathode will be positioned over the right (contralateral) supraorbital area. For the other 8 participants the stimulation montages were similar to cerebellar stimulation group. The active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right Buccinator Muscle.
Study: NCT05646823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic blend
Description: Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle only - Maltodextrin gluten free
Study: NCT04964739

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy (CBT4CBT)
Description: Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy (CBT4CBT)
Description: Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
Study: NCT05374785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL409116
Description: CPL409116 contained in the tablet called PG242 (60 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL409116
Description: CPL409116 contained in the tablet called PG242 (60 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL409116
Description: CPL409116 contained in the tablet called PG242 (60 mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets without CPL409116 as an active substance
Study: NCT06269263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Description: Guided by physiotherapists, patients will receive different trainings regrading endurance/balance/resistance,/coordination at home
Study: NCT06321341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vespireit
Description: Buspirone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arlevert
Description: Dimenhydrinate + Cinnarizine
Study: NCT05045378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam (active placebo)
Description: Arm1: Two 0.045mg/kg midazolam infusions at Day1 and Day3。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine and Midazolam (active placebo)
Description: Arm2: First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Arm3: Two 0.5mg/kg ketamine infusions。
Study: NCT05055336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stomach ultrasound
Description: Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stomach ultrasound
Description: Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
Study: NCT05875077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
Study: NCT05946772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: 2.5mg/kg body weight Cyclosporine A as an intravenous bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same amount of 0.9% sodium chloride (NaCl0.9%) will be applied in an indistinguishable package as an intravenous bolus
Study: NCT06035497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days
Study: NCT05100147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine closure during Cesarean section
Description: The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine closure during Cesarean section
Description: The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
Study: NCT04932798

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting ECG (if first visit is done on site only)
Description: The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time.

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting ECG (if first visit is done on site only)
Description: The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)
Description: The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)
Description: The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3-month AF detection monitoring using the Apple Watch
Description: Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3-month AF detection monitoring using the Apple Watch
Description: Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.
Study: NCT05100147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine closure during Cesarean section
Description: The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
Study: NCT05281640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Dysregulation intervention
Description: See relevant study arm for description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Self Concept intervention
Description: See relevant study arm for description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disturbed Relationships intervention
Description: See relevant study arm for description
Study: NCT06326918

Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal mucosal brushing
Description: Duodenal mucosal brushing will be performed at duodenal bulb.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal mucosal brushing
Description: Duodenal mucosal brushing will be performed at duodenal bulb.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal mucosal biopsy
Description: Duodenal mucosal biopsy will be performed at duodenal bulb.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal mucosal biopsy
Description: Duodenal mucosal biopsy will be performed at duodenal bulb.
Study: NCT06386549

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tele-rehabilitation
Description: Using the social networking tool WeChat, families of children with burns are educated and trained through texts, photos, voice messages, and live videos, twice a week for a total of 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-rehabilitation
Description: Using the social networking tool WeChat, families of children with burns are educated and trained through texts, photos, voice messages, and live videos, twice a week for a total of 12 weeks
Study: NCT04802785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citicoline 500 mg (Vitaae®) per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytochrome C6
Description: Cytochrome10 mg per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride Oral Product
Description: Sodium Chloride (NaCl) 2.6 g. per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Chloride Oral Product
Description: Potassium Chloride 1.5 g per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate Oral Product
Description: Sodium Citrate 2.90 g per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose Oral Tablet, Chewable
Description: Dextrose 13.5 g per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone Oral Product
Description: Domperidone 1 tablet per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: 3-4 capsules per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 150 mg per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide
Description: magnesium hydroxide 30 mg per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Description: 1 capsule per os.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 mg
Description: Melatonin 5 mg per os.
Study: NCT05224648

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF scan train of four ratio monitoring
Description: Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITF device tetanus stimulation monitoring
Description: Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
Study: NCT05380570

Intervention type: RADIATION
Intervention: Occupational radiation exposure
Description: Ionizing radiation in workplaces
Study: NCT05236595

Intervention type: OTHER
Intervention: Individualized drug matching per genetic disease
Description: Patient phenotype and samples will be evaluated for individualized therapeutic drug development
Study: NCT05415709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT06468917

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1st day removal of abdominal drain
Description: once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1st day removal of abdominal drain
Description: once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed
Study: NCT04763408

Intervention type: DRUG
Intervention: Lenvatinib
Description: Oral capsules.

Intervention type: DRUG
Intervention: Sorafenib
Description: Oral tablets.
Study: NCT05540600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Description: Patients will have the dose of one tablet of 0.25mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
Study: NCT05415709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Surgery
Description: Undergo CRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Undergo CRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Undergo CRS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: Undergo HIPEC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06265480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FallFitness intervention group
Description: Eight week group-based fallprevention intervention. A total of eight session (1-hour once a week).
Study: NCT06328231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic simple swallowing training
Description: Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week.
Study: NCT05470725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
Study: NCT05469061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m\^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis Platinum
Description: A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
Study: NCT05032105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)
Description: Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
Study: NCT04634175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body intervention
Description: The mind-body intervention is composed of kundalini yoga techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham intervention
Description: The sham intervention is composed of stretching and muscle flexion techniques.
Study: NCT06499909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The patient will receive a course of hypnosis